Last reviewed · How we verify
NCT05619861
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Status unknown
NA
Last updated 17 November 2022
What this trial tests
NA trial testing CAR-T in Lymphoma, B-Cell in 20 participants. Status unknown.
Timeline
27 April 2020
Primary endpoint
26 January 2023
26 January 2023
26 December 2023
Quick facts
| Lead sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 27 April 2020 |
| Primary completion | 26 January 2023 |
| Estimated completion | 26 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T — full drug profile →
Conditions studied
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
- Leukemia, B-cell — all drugs for Leukemia, B-cell →
- Leukemia, T-Cell — all drugs for Leukemia, T-Cell →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Hebei Senlang Biotechnology Inc., Ltd. — full company profile →
Who can join
Adults 14 to 70, any sex, with Lymphoma, B-Cell or Leukemia, B-cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M, Nowak E, Twardowska J, Lejman M, et al · · 2023 · cited 5× · PMID 38003910 · DOI 10.3390/jpm13111595 -
Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up.
Li LL, Xia YP, Li Q, Wang P, et al · · 2024 · cited 1× · PMID 39620223 · DOI 10.3389/fimmu.2024.1469251 -
Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review.
Karimi A, Kazemi-Harikandei SZ, Alilou S, Salabat D, et al · · 2025 · PMID 41354926 · DOI 10.1186/s12935-025-04090-5
Verify or expand the search:
- PubMed search for NCT05619861
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T
Trials testing the same drug.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
- NCT07441291 — CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT · Phase 3 · recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting
Other recruiting trials for Lymphoma, B-Cell
Currently open trials in the same condition.
- NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
- NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
- NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
- NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
Other Hebei Senlang Biotechnology Inc., Ltd. trials
Trials by the same sponsor.
- NCT07435779 — Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study · EARLY_PHASE1 · recruiting
- NCT07421856 — Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. · Phase 1, PHASE2 · not yet recruiting
- NCT07244380 — Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. · Phase 2 · not yet recruiting
- NCT07161193 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases · Phase 1, PHASE2 · not yet recruiting
- NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05619861 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Senlang Biotechnology Inc., Ltd.
- Last refreshed: 17 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05619861.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing